681P Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer (BCRpc)
Ravi A. Madan(National Cancer Institute), James L. Gulley(National Cancer Institute), William L. Dahut(National Cancer Institute), Julius Strauss(National Cancer Institute), Susan F. Slovin(Cornell University), Lisa M. Cordes(National Institutes of Health Clinical Center), Amy Hankin(National Institutes of Health), Xiao X. Wei(Dana-Farber Cancer Institute), Marijo Bilušić(National Institutes of Health), Renee N. Donahue(National Institutes of Health), Lauren C. Harshman(Dana-Farber Cancer Institute), Philip W. Kantoff(Convergent Science (United States)), Jeffrey Schlom(National Cancer Institute), Fatima Karzai(National Institutes of Health), Susan Wróblewski(National Institutes of Health), Philip M. Arlen(Dana-Farber Cancer Institute), N. Williams(National Institute of Allergy and Infectious Diseases), Myrna Rauckhorst(National Institutes of Health), Anna Couvillon(National Institutes of Health), Nicole J. Toney(National Institutes of Health)
Cited by 3
Related Papers
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k